TRAIL/TNFSF10, Human

TRAIL Protein (TNFSF10), a member of the TNF superfamily, is a type II transmembrane protein. TRAIL Protein mainly interacts with TRAIL-R1 and TRAIL-R2, and induces apoptosis in tumor or infected cells. TRAIL Protein also binds with DR4, DR5, and OPG. TRAIL Protein can recruit FADD and further recruit and activates caspase-8 after binding to DR4 or DR5. Besides, TRAIL may also trigger nonapoptotic signaling through activating pro-inflammatory pathways[1][2]. TRAIL protein is mainly expressed on surface of immune cells, such as cytotoxic T cells and natural killer (NK) cell[1]. TRAIL/TNFSF10 Protein, Human is a recombinant human TRAIL (V114-G281) without any tag, which is expressed in E. coli.

VRERGPQRVA AHITGTRGRS NTLSSPNSKN EKALGRKINS WESSRSGHSF LSNLHLRNGE LVIHEKGFYY IYSQTYFRFQ EEIKENTKND KQMVQYIYKY TSYPDPILLM KSARNSCWSK DAEYGLYSIY QGGIFELKEN DRIFVSVTNE HLIDMDHEAS FFGAFLVG

[1]Almasan A, et al. Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy. Cytokine Growth Factor Rev. 2003 Jun-Aug;14(3-4):337-48.|[2]Braithwaite, Adam T, et al. "Divergent Roles for TRAIL in Lung Diseases". Frontiers in Medicine. Allan (2018)|[3]Cardoso Alves L, et al. The multifaceted role of TRAIL signaling in cancer and immunity. FEBS J. 2021 Oct;288(19):5530-5554.|[4]Zhong HH, et al. TRAIL-based gene delivery and therapeutic strategies. Acta Pharmacol Sin. 2019 Nov;40(11):1373-1385.|[5]Snajdauf M, et al. The TRAIL in the Treatment of Human Cancer: An Update on Clinical Trials. Front Mol Biosci. 2021 Mar 10;8:628332. |[6]Ganten TM, et al. Preclinical differentiation between apparently safe and potentially hepatotoxic applications of TRAIL either alone or in combination with chemotherapeutic drugs. Clin Cancer Res. 2006 Apr 15;12(8):2640-6. |[7]Weckmann M, et al. Critical link between TRAIL and CCL20 for the activation of TH2 cells and the expression of allergic airway disease. Nat Med. 2007 Nov;13(11):1308-15.